ZYLiQ is going to give medical writers what they need - time. No more spending weeks creating Clinical Study Reports (CSRs); Medical Writers can now use their valuable time on interpretation of study results and their discussion points.

The premise is simple... Using AI, ZYLiQ allows users to automatically generate CSRs (according to ICH E3 guidelines) that would otherwise take days or months even.  The tool allows for easy Post-Text to In-Text table generation, with interpretation of tables, Synopsis summarisation, automatic tense conversion, multi-authoring, consolidated view of reviewers comments and more.

ZYLiQ also has robust workflow functions, traceability reporting as well as a complete audit log. Let ZYLiQ accomplish the tedious manual “copy/paste” aspects of a CSR and allow you to complete the report accurately and efficiently, in days instead of weeks.

For more than 135 years, Johnson & Johnson (the “Company”) (NYSE: JNJ) has provided health care products and solutions to people worldwide.
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. 

Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Our diverse portfolio spans multiple therapeutic areas—Oncology, Immunology, Neuroscience, Cardiovascular, Pulmonary Hypertension, and Retina. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. Patients inform and inspire our science-based innovations, which continue to change and save lives.

Learn more at https://www.jnj.com/.

Parexel is among the world’s largest clinical research organisations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals collaborates with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas, while our innovation ecosystem offers the best solutions to make every phase of the clinical trial process more efficient. With the people, insight and focus on operational excellence, we work With HeartTM every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference. For more information, visit parexel.com and follow us on LinkedIn, Twitter, Facebook and Instagram. 

Yseop is the leader in Generative AI for life science and pharmaceutical companies, changing the way content automation solutions are delivered with a human-centric, AI platform. Yseop is a pioneer in Natural Language Processing (NLP) technology and acts as a “Copilot” for medical writers, maximizing their efficiency and accuracy in generating reports and insights crucial to drug development and approval. With cutting-edge language models, Yseop ensures today’s pharmaceutical companies are meeting the most demanding content tasks with ease, scalability and application security. As the world’s leading content automation solution for biopharmaceuticals. Yseop Copilot is a digital colleague that empowers scientific writers and addresses the unique requirements of the highly regulated pharmaceutical industry. Blending the power of language models with customer data, Yseop Copilot delivers trusted and auditable content automation solutions in a closed, secure environment.